Latest From Danaher Corp.
Growth gaps and a desire to concentrate on a small number of therapeutic areas are expected to continue to drive M&A in 2020, but thought needs to be given to investing in data-driven and digital technologies, a new EY report says.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.
Investors at Alliance for Regenerative Medicine’s Investor Day in March 2019 were bullish on cell and gene therapies, but some worry about the market overcrowding.
- In Vitro Diagnostics
- Medical Devices
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Beckman Coulter Inc.
- Genetix Group PLC
- Leica AG
- MDS Analytical Technologies
- Nobel Biocare Holding AG
- Pall Corp.
- Radiometer Medical APS
- Sybron Dental Specialties Inc.
- Senior Management
Thomas P Joyce, Jr., Pres. & CEO
Matt McGrew, EVP, CFO
Daniel A Raskas, SVP, Corp. Dev.
William H King, IV, SVP, Strategic Dev.
- Contact Info
Phone: (202) 828-0850
2200 Pennsylvania Ave. NW
Washington, DC 20037-1701
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.